We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+4.95%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$811M
AUM Growth
+$130M
Cap. Flow
+$109M
Cap. Flow %
13.4%
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
INGN icon
Inogen
INGN
+$96.4M
2
FLXN
Flexion Therapeutics, Inc.
FLXN
+$30.8M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$12.8M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 47.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$655B
$290M 35.8%
2,979,100
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$246M 30.34%
6,896,819
– –
VGK icon
3
Vanguard FTSE Europe ETF
VGK
$30.1B
$124M 15.27%
2,101,000
– –
INGN icon
4
Inogen
INGN
$171M
$89.5M 11.03%
+5,419,449
New +$96.4M
FLXN
5
DELISTED
Flexion Therapeutics, Inc.
FLXN
$29.3M 3.62%
+1,783,131
New +$30.8M
WMGI
6
DELISTED
Wright Medical Group Inc
WMGI
$18.2M 2.24%
585,759
– –
TTPH
7
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$9.8M 1.21%
45,000
-15,000
-25% -$4.18M
PTCT icon
8
PTC Therapeutics
PTCT
$6.29B
– –
-597,359
Closed -$12.8M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q1 2014 Portfolio in Review

As of Q1 2014, Novo Holdings A/S held 9 positions worth $811M, up 19% from $681M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Novo Holdings A/S deployed $109M of net new capital in Q1 2014, opening 2 new positions. Its largest new stake was Inogen: 5,419,449 shares worth $89.5M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 37% a quarter earlier.

On the sell side, the largest reduction was Tetraphase Pharmaceuticals, Inc., an estimated $4.18M trimmed.

  • Novo Holdings A/S's largest Q1 2014 buy was Inogen: 5,419,449 shares worth $89.5M.
  • Novo Holdings A/S's biggest Q1 2014 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $4.18M.
  • Novo Holdings A/S fully exited PTC Therapeutics in Q1 2014, selling an estimated $12.8M.
  • Novo Holdings A/S's ten largest holdings make up 100% of its $811M portfolio in Q1 2014.
  • Novo Holdings A/S opened 2 new positions and closed 1 in Q1 2014.
  • Novo Holdings A/S's portfolio value rose 19% quarter-over-quarter to $811M.

Based on Novo Holdings A/S's 13F filing for Q1 2014, filed 14 Aug 2014.